Artiva Biotherapeutics is leveraging GC LabCell’s cell therapy technology to target cancer, and has raised series A funding from backers including the latter.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

SoftBank Vision Fund owns more than 40% of the precision cancer drug developer, which raised $400m approximately 18 months ago.

The 6 Dimensions Capital-backed cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.

Gilead Sciences will invest $275m in return for a 49.9% stake as part of a deal that could see it purchase the cancer immunotherapy developer outright.

Sana Biotechnology has closed its first round at more than $700m after investors including GV swung behind its vision to commercialise cell therapies.

The kidney care services provider has now collected more than $105m to date, Optum Ventures co-leading a round also featuring Blue Venture Fund.

Existing backer Bristol Myers Squibb returned to commit to healthcare venture firm BioGeneration Ventures' oversubscribed BGV IV vehicle.

Chiesi chipped in as the drug discovery platform developer closed a series B round that will fund its expansion into the agrochemical industry.

Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.